- Home
- MRCY vs PTGX Comparison
MRCY vs PTGX Comparison
Compare MRCY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCY | PTGX |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.4B |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MRCY | PTGX |
|---|---|---|
| Price | $74.45 | $89.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $76.43 | ★ $90.56 |
| AVG Volume (30 Days) | 619.2K | ★ 1.0M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $932,798,000.00 | $209,217,000.00 |
| Revenue This Year | $6.47 | N/A |
| Revenue Next Year | $8.65 | $288.98 |
| P/E Ratio | ★ N/A | $123.35 |
| Revenue Growth | ★ 8.63 | N/A |
| 52 Week Low | $39.42 | $33.70 |
| 52 Week High | $85.33 | $96.54 |
Technical Indicators
Market Signals| Indicator | MRCY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 55.09 |
| Support Level | $68.81 | $84.11 |
| Resistance Level | $75.78 | $90.00 |
| Average True Range (ATR) | 2.63 | 3.27 |
| MACD | 0.42 | -0.65 |
| Stochastic Oscillator | 64.00 | 41.92 |
Price Performance
Historical ComparisonAbout MRCY Mercury Systems Inc
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.